Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07378527RecruitingPhase 2/Phase 3
Study of ICP-332 for chronic hives not helped by antihistamines
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
Bengbu, AnhuiAges 18–75 - NCT07379047RecruitingPhase 2/Phase 3
Testing NB003 for advanced GIST after prior treatments
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
Hefei, AnhuiAges 18 years+ - NCT07379333RecruitingPhase 3
Testing a new drug for type 2 diabetes when metformin and dapagliflozin aren't enough
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
Gyeonggi-doAges 19 years+ - NCT07382973Recruiting
NTP safety in thyroid surgery: preventing complications
This trial is testing if a technology called NTP (a type of low-temperature plasma) can help prevent complications and improve cancer control when they remove all or part of the thyroid gland. It's for adults having thyroid surgery.
Ocoyoacac, State of MexicoAges 18 years+ - NCT07385625Recruiting
Studying a new device for severe tricuspid valve leakage
This trial tests a device called the Pivot Bridge System to treat severe leakage of the tricuspid valve (the valve between the right upper and lower heart chambers). The goal is to see if it safely reduces symptoms like swelling and shortness of breath.
Daegu, Dalseo-guAges 18 years+ - NCT07385703RecruitingPhase 3
A trial of LM-302 with tislelizumab for stomach cancer
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
Hefei, AnhuiAges 18 years+ - NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07389980RecruitingPhase 3
Personalized high-dose aflibercept for a type of wet AMD
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
DaeguAges 19 years+ - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT07390500RecruitingPhase 2
Myopia control study for children using digital devices
This study tests a special lens designed to slow down nearsightedness (myopia) in children. It is for kids who spend at least one hour a day on screens and currently wear regular glasses.
RehovotAges 6–12 - NCT07391241RecruitingPhase 2
Pudafensine for vulvar pain study
This trial tests a new medicine called pudafensine to see if it safely reduces pain in women with vulvodynia, a condition that causes pain when the vulvar area is touched.
BlackpoolAges 18–65 - NCT07392957RecruitingPhase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
St Louis, MissouriAges 18 years+ - NCT07395960RecruitingPhase 1/Phase 2
Metformin for older adults with mild memory loss and higher weight
This trial tests if metformin can help older adults (60-75) who are overweight and have mild memory problems. It aims to see if the drug can slow down or improve memory issues.
ShanghaiAges 60–75 - NCT07396155RecruitingPhase 1/Phase 2
Stem cell therapy for diabetic kidney disease
This trial tests whether stem cells from donated umbilical cords can safely help people with type 2 diabetes who also have kidney damage. It aims to see if this therapy can improve kidney function.
YogyakartaAges 30–65 - NCT07396337RecruitingPhase 2
Study of QHRD106 injection for acute ischemic stroke
This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.
Nanjing, JiangsuAges 18–80 - NCT01297400RecruitingPhase 2
Testing a topical treatment for thermal burns
This trial studies whether a topical medicine (MW-III) is safe and helps heal thermal burns. It is for adults with relatively limited burn size and certain burn depths, while excluding infected or high-risk wounds.
Phoenix, ArizonaAges 18 years+ - NCT01906385RecruitingPhase 1/Phase 2
Recurrent brain tumor study testing rhenium nano-liposome
This early-phase study tests a drug made of tiny fat-like particles carrying rhenium for recurrent (coming back) high-grade glioma. It mainly checks safety and the highest tolerable dose, and it also looks for signs the treatment may slow tumor growth.
Manhasset, New YorkAges 18 years+ - NCT02726555RecruitingPhase 3
Red yeast rice plus low-dose statin versus statin alone
This Phase 3 study compares whether taking red yeast rice plus a low-dose statin works better and is as safe as taking a standard statin alone. It aims to improve cholesterol (especially LDL) and reduce cardiovascular risk in people with mild, confirmed artery disease.
Wenzhou, ZhejiangAges 20–80 - NCT02638389RecruitingPhase 3
Sirolimus for hard-to-treat vascular birthmarks
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Brussels, Brussels CapitalAges 3 months–70 years - NCT07213973RecruitingPhase 2
Study of povorcitinib for teens with hidradenitis suppurativa
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
Birmingham, AlabamaAges 12–17 - NCT07676565Recruiting
Adding new drugs to insulin for type 1 diabetes
This study tests whether adding certain diabetes pills (GLP-1 receptor agonists or SGLT inhibitors) to insulin is safe and helpful for adults with type 1 diabetes. Doctors will check your glucose monitor data to see how well this works.
Newport Beach, CaliforniaAges 18 years+ - NCT07204639RecruitingPhase 2
Testing CBP-0276 for moderate to severe psoriasis
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
Mexico CityAges 18–70 - NCT05951179RecruitingPhase 2
Bladder instillation study for high-grade non–muscle-invasive cancer
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
Homewood, AlabamaAges 18 years+ - NCT07056777RecruitingPhase 1/Phase 2
DR30206 plus standard therapy for advanced GI cancer
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
Guangzhou, GuangdongAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.